Caregivers’ and physicians’ attitudes to rotigotine transdermal patch versus oral Parkinson’s disease medication: an observational study

References

• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011;26:399-406
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Odin P, Antonini A, et al. Parkinson's disease: the non-motor issues. Parkinsonism Relat Disord 2011;17:717-23
   PubMed Web of Science ®Google Scholar
• Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J Neurol 2012;259:2621-31
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ. Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors. Expert Rev Pharmacoecon Outcomes Res 2012;12:221-30
   PubMed Web of Science ®Google Scholar
• Tse W, Frisina PG, Halbig TD, et al. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J Am Med Dir Assoc 2008;9:670-5
   PubMed Web of Science ®Google Scholar
• van Rumund A, Weerkamp N, Tissingh G, et al. Perspectives on Parkinson Disease Care in Dutch Nursing Homes. J Am Med Dir Assoc 2014;15:732-7
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatrics Soc 2000;48:938-42
   PubMed Web of Science ®Google Scholar
• Grosset D. Therapy adherence issues in Parkinson's disease. J Neurol Sci 2010;289:115-18
   PubMed Web of Science ®Google Scholar
• Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009;24:826-32
   PubMed Web of Science ®Google Scholar
• Fargel M, Grobe B, Oesterle E, et al. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Investig 2007;27:207-18
   PubMed Web of Science ®Google Scholar
• Leopold NA, Polansky M, Hurka MR. Drug adherence in Parkinson's disease. Mov Disord 2004;19:513-17
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Therapeut 2012;34:966-78
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22:2398-404
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64:676-82
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68:272-6
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007;6:513-20
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007;68:1262-7
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Neupro: EPAR Product Information. Summary of Product Characteristics. UCB Manufacturing Ireland Ltd, Ireland; first published 21 December 2009
   Google Scholar
• Abetz L, Rofail D, Mertzanis P, et al. Alzheimer's disease treatment: assessing caregiver preferences for mode of treatment delivery. Adv Ther 2009;26:627-44
   PubMed Web of Science ®Google Scholar
• Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatr 2007;22:485-91
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson's disease. Mov Disord 2007;22:924-31; quiz 1060
   PubMed Web of Science ®Google Scholar
• Wüllner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transmission 2010;117:855-9
   PubMed Web of Science ®Google Scholar
• Cawello W, Ahrweiler S, Sulowicz W, et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012;73:46-54
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Reichmann H, Boroojerdi B, et al. Rotigotine transdermal system for perioperative administration. J Neural Transmission 2007;114:219-21
   PubMed Web of Science ®Google Scholar
• Wullner U, Fuchs G, Reketat N, et al. Requirements for Parkinson's disease pharmacotherapy from the patients' perspective: a questionnaire-based survey. Curr Med Res Opin 2012;28:1239-46
   PubMed Web of Science ®Google Scholar
• Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions. Int J Clin Pract 2014;68:465-70
   PubMed Web of Science ®Google Scholar
• Schnitzler A, Leffers KW, Hack HJ. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinsonism Relat Disord 2010;16:513-16
   PubMed Web of Science ®Google Scholar